Question · asked by 1 review
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone (radiotherapy or chemoradiotherapy): Adverse effects
- Population
- People with squamous cell carcinoma of the oral cavity or oropharynx
- Intervention
- Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy
- Comparison
- Standard therapy alone (radiotherapy or chemoradiotherapy)
- Outcome
- Adverse effects
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported.
What each review found
Current versions onlyNo studies found 0 · 0%GRADE not reported 9 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Moderate to severe chills (BCG-CWP, all grades) Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 11.00 [0.67, 179.29] | 1 study · 24 participants | GRADE not reported |
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Nausea/vomiting (rIL-2, grades >=3) Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 3.40 [0.15, 77.34] | 1 study · 30 participants | GRADE not reported |
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Stomatitis (rIL-2, all grades) Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 1.47 [0.75, 2.90] | 1 study · 30 participants | GRADE not reported |
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Leukopenia (rIL-2, all grades) Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 0.57 [0.22, 1.50] | 1 study · 30 participants | GRADE not reported |
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Increased temperature (BCG-CWP, all grades) Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 0.67 [0.13, 3.30] | 1 study · 24 participants | GRADE not reported |
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Leukopenia (rIL-2, grades >=3) Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 0.38 [0.04, 3.26] | 1 study · 30 participants | GRADE not reported |
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Nausea/vomiting (rIL-2, all grades) Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 1.24 [0.90, 1.70] | 1 study · 30 participants | GRADE not reported |
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Stomatitis (rIL-2, grades >=3) Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 1.71 [0.33, 8.83] | 1 study · 30 participants | GRADE not reported |
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 24 to 70 months, Gastrointestinal complaints (BCG-CWP, all grades) Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 5.00 [0.27, 94.34] | 1 study · 24 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes | 2015-02 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.